BMI1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using BMI1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.    

  
  

•  

   

     Flow cytometric analysis of NIH/3T3 cells using BMI1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using BMI1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using BMI1 mouse mAb with DAB staining.    

  
  

The BMI1 antibody is a crucial tool in studying the polycomb repressive complex 1 (PRC1), a key epigenetic regulator involved in gene silencing. BMI1. a core component of PRC1. facilitates monoubiquitination of histone H2A, maintaining transcriptional repression of target genes, including tumor suppressors like p16INK4a and p14ARF. It plays vital roles in stem cell self-renewal, differentiation, and oncogenesis, with overexpression linked to cancer progression, therapy resistance, and poor prognosis in malignancies such as glioblastoma, breast cancer, and leukemia.

BMI1 antibodies are widely used in research to detect protein expression via techniques like immunohistochemistry, Western blotting, and flow cytometry. They help elucidate BMI1's role in maintaining cancer stem cell populations and its association with aggressive tumor phenotypes. Additionally, these antibodies aid in exploring BMI1's interaction with other polycomb group proteins and its regulatory mechanisms in chromatin remodeling.

In clinical contexts, BMI1 expression levels, assessed using specific antibodies, may serve as a biomarker for disease stratification or therapeutic targeting. Recent studies also investigate BMI1 inhibition as a strategy to sensitize cancer cells to chemotherapy or radiation. However, antibody specificity and validation remain critical, as cross-reactivity with homologous proteins can affect data interpretation. Overall, BMI1 antibodies are indispensable for advancing both basic and translational research in epigenetics and oncology.